Journal article
Use of HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells as a Potential Therapeutic for Progressive HER2-Positive Glioblastoma.
Authors
Schneider JR; Kwan K; Boockvar JA
Journal
Neurosurgery, Vol. 81, No. 5, pp. n42–n43
Publisher
Wolters Kluwer
Publication Date
November 1, 2017
DOI
10.1093/neuros/nyx449
ISSN
0148-396X